Combining Biologics Targeting Eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in Allergic and Inflammatory Diseases

Combining Biologics Targeting Eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in Allergic and Inflammatory Diseases

The indications for biologic therapy are expanding. Patients may benefit from different biologics for separate conditions or one condition with multiple pathogenic mechanisms targeted by different biologics. We sought to determine the frequency and safety of combining biologics targeting IgE, IL-5,...

Full description

Bibliographic Details
Main Authors: Mitchell M. Pitlick, MD, Thanai Pongdee, MD
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:World Allergy Organization Journal
Subjects:
Biologic
Eosinophils
Omalizumab
Benralizumab
Mepolizumab
Dupilumab
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455122000837

Internet

http://www.sciencedirect.com/science/article/pii/S1939455122000837

Similar Items